The Brazilian medical device market, one of the largest in Latin America, offers significant opportunities for international manufacturers. However, success in this market requires an in-depth understanding of the regulatory landscape, overseen by ANVISA (National Health Surveillance Agency).  The Brazilian regulatory framework for medical devices is based on several key resolutions (RDCs). RDC 185/2001 establishes the fundamental requirements for medical device registration, while more recent regulations, such as RDC 751/2022 and RDC 665/2022,, have introduced important updates to the regulatory framework.  ANVISA places great emphasis on Good Manufacturing Practices (GMP) certification. International manufacturers must demonstrate compliance with Brazilian GMP requirements, which align with international standards but also include country-specific elements. The certification process typically involves:  Device Risk Classification  Overview of the Registration Process  The registration process for medical devices in Brazil involves several key steps:  Considerations for Software as a Medical Device (SaMD)  With the rise of digital health solutions, ANVISA has developed specific requirements for Software as a Medical Device (SaMD). These products require specialized documentation and risk evaluation approaches, focusing on:  Laboratory-Developed Tests and In Vitro Diagnostics  The regulation of Laboratory-Developed Tests has gained increasing importance in the Brazilian healthcare system. Manufacturers must meet specific requirements, ensuring compliance with international standards and local market demands.  Market Access Strategies  Success in entering the market requires more than regulatory compliance. Companies should consider:  Working with Regulatory Specialists  Given the complexity of the Brazilian regulatory environment, many international companies choose to work with specialized medical device consultancies. These partnerships can provide:  Conclusion  Navigating Brazil’s medical device regulatory framework requires careful planning, thorough understanding, and often local expertise. While the process can be complex, the potential rewards of accessing one of Latin America’s largest healthcare markets make it a worthwhile endeavor for many international manufacturers.  For companies seeking to enter or expand in the Brazilian market, working with experienced regulatory partners can significantly streamline the process and improve chances of success. These partners can provide crucial insights into both regulatory requirements and market access strategies, ensuring a more efficient path to market.  Contact our regulatory experts to discuss your specific needs and develop a tailored strategy for your medical device registration in Brazil.    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

Are you a medical device executive looking to understand how medical devices are classified in Brazil? This comprehensive guide will walk you through ANVISA’s classification system and requirements, helping you navigate the Brazilian regulatory landscape effectively.  The Brazilian Regulatory Framework  Brazil’s medical device market, regulated by ANVISA (Brazilian Health Regulatory Agency), operates under specific guidelines that ensure product safety and efficacy. Understanding these classifications is crucial for successful market entry and regulatory compliance.  Risk Classification System  ANVISA’s medical device classification follows both risk categories and specific classification rules as defined in RDC 751/2022: Class I (Low Risk) Class II (Medium Risk) Class III (High Risk) Class IV (Maximum Risk) Classification Rules Structure The 22 classification rules are organized into four main categories: Note: Detailed classification rules can be found in Annex I of RDC 751/2022. Analysis timeframes are estimates and may vary based on ANVISA’s current workload. GMP Requirements and MDSAP Considerations  For higher-risk devices (Classes III and IV), manufacturers must demonstrate compliance with Good Manufacturing Practices (GMP). Brazil participates in the Medical Device Single Audit Program (MDSAP), which can streamline the certification process for international manufacturers. To learn more about this topic, click here.  Software as a Medical Device (SaMD)  With the increasing prevalence of digital health solutions, ANVISA has specific requirements for Software as a Medical Device (SaMD). These products must undergo classification and registration based on their intended use and potential risk.  Laboratory Developed Tests Considerations  For manufacturers dealing with laboratory developed tests, additional requirements apply under specific ANVISA regulations. These products require special attention to classification and validation requirements.  Registration Process and Documentation  The registration process varies by classification:  Market Access Strategy  Successful market entry requires:  For expert guidance on medical device registration and regulatory compliance in Brazil, contact Brisa Advisors for specialized regulatory support.    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

Medical device manufacturers seeking to enter the Brazilian market must navigate a complex regulatory landscape overseen by ANVISA (Agência Nacional de Vigilância Sanitária) in Brasilia. Understanding this regulatory framework is crucial for successful market access and compliance in Latin America’s largest healthcare market.  Regulatory Framework and Authority  ANVISA, established by Law No. 9,782 in 1999, operates as an independent regulatory agency under the Ministry of Health. The agency’s primary mission encompasses protecting public health through comprehensive regulation of medical devices and other healthcare products. This regulatory oversight includes several key areas:  Registration and Classification System  Medical devices in Brazil must undergo a thorough registration process based on their risk classification (Classes I through IV). This process is governed by various regulatory directives (RDCs), including:  Good Manufacturing Practices (GMP)  ANVISA requires manufacturers to maintain strict adherence to Good Manufacturing Practice (GMP) standards, which align with international requirements like ISO 13485. This certification process includes:  Software as a Medical Device (SaMD)  With the increasing prevalence of digital health solutions, ANVISA has developed specific regulations for Software as a Medical Device (SaMD). These requirements include:  Market Access Considerations  For international manufacturers, working with experienced medical device consulting firms can significantly streamline the registration process. Key considerations include:  Laboratory Developed Tests and IFUs  The regulation of Laboratory Developed Tests requires specific attention to:  Medical Device Unique Device Identification(UDI)  ANVISA’s implementation of UDI requirements aligns with global standards and includes:  International Harmonization  ANVISA actively participates in international regulatory harmonization efforts, including:  MDSAP Participation  The Medical Device Single Audit Program (MDSAP) acceptance demonstrates ANVISA’s commitment to:  Health Sciences Authority Collaboration  ANVISA maintains partnerships with various international regulatory bodies, including:  Contact and Support  For manufacturers seeking regulatory support in Brazil, maintaining direct contact with ANVISA through official channels is essential. The agency provides various support mechanisms:  Conclusion  Successfully navigating ANVISA’s regulatory requirements demands a comprehensive understanding of both technical and procedural aspects. International manufacturers should consider partnering with experienced regulatory consultants to ensure compliance and optimize their market access strategy in Brazil.  For expert guidance on medical device registration and regulatory compliance in Brazil,, contact Brisa Advisors for specialized regulatory support.    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

In today’s modern healthcare landscape, medical devices play a pivotal role in patient care, diagnostics, and treatment. However, bringing these devices to market requires navigating complex regulatory frameworks designed to ensure patient safety and product efficacy. Understanding the intricacies of medical device registration is crucial for manufacturers looking to enter new markets while maintaining compliance with regulatory requirements.  The Foundation of Medical Device Safety  The journey of a medical device from development to market involves rigorous regulatory oversight. Health products regulatory authorities worldwide, including ANVISA in Brazil, the FDA in the United States, and other prominent health sciences authorities, have established comprehensive frameworks to evaluate and monitor medical devices. These frameworks serve as gatekeepers, ensuring that only safe and effective devices reach healthcare providers and patients.  Key Components of Medical Device Registration  GMP Compliance and Quality Management  Good Manufacturing Practice (GMP) certification stands as a cornerstone of medical device registration. Manufacturers must demonstrate robust quality management systems that align with international standards. This includes:  Technical Documentation Requirements  Successful registration requires comprehensive technical documentation that includes:  Regulatory Compliance and Standards  In Brazil, manufacturers must navigate specific regulatory requirements, including:  MDSAP and International Recognition  The Medical Device Single Audit Program (MDSAP) has become increasingly important for manufacturers seeking market access across multiple jurisdictions. This program allows for a single regulatory audit to satisfy the requirements of multiple regulatory authorities, streamlining the compliance process.  Critical Considerations for Manufacturers  Risk Classification and Documentation  Medical devices are categorized based on their risk level, which determines the extent of documentation and testing required for registration. Higher-risk devices typically require:  Laboratory Developed Tests  For manufacturers dealing with laboratory developed tests, special considerations apply regarding validation, verification, and quality control measures. These requirements ensure the accuracy and reliability of diagnostic results.See more about the step by step by clicking here.  Post-Market Surveillance  Maintaining registration requires ongoing vigilance through:  Unique Device Identification (UDI) Implementation  The implementation of UDI systems has become a crucial aspect of medical device registration and traceability. This system helps:  Strategic Approach to Registration  Market Access Strategy  Developing a comprehensive market access strategy involves:  Professional Support and Consultation  Given the complexity of medical device registration, many manufacturers benefit from:  Conclusion  Successfully navigating medical device registration requires a thorough understanding of regulatory requirements, quality standards, and market-specific considerations. By prioritizing compliance and maintaining robust quality management systems, manufacturers can ensure their devices meet the necessary safety and efficacy standards while efficiently accessing their target markets.  For manufacturers seeking to enter the Brazilian market or expand their presence, understanding ANVISA’s requirements and working with experienced regulatory professionals can significantly streamline the registration process. This investment in proper registration procedures not only ensures regulatory compliance but also builds trust with healthcare providers and patients, ultimately contributing to better healthcare outcomes.  For expert guidance on medical device registration and regulatory compliance in Brazil, contact specialized regulatory affairs consultants who can provide comprehensive support throughout the registration process.  For expert guidance on medical device registration and regulatory compliance in Brazil,, contact Brisa Advisors for specialized regulatory support.    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

The medical devices (MD) sector in Brazil plays a crucial role in public and private healthcare, providing essential technologies for patient diagnosis, treatment, and monitoring. To ensure the sustainable and ethical development of the sector, various representative institutions act as pillars of regulation, innovation, and best practices. This article explores the main associations and organizations shaping the medical devices market in the country.  ABIMED: Brazilian Association of the Medical Technology Industry  Founded in 1996, ABIMED is one of the leading entities in the sector, representing around 200 companies involved in medical technologies. Its mission includes:  ABIMO: Brazilian Association of the Medical Devices Industry  ABIMO represents national companies engaged in manufacturing medical, dental, hospital, and laboratory devices. Focusing on promoting domestic industry, the association seeks to:  CBDL: Brazilian Chamber of Laboratory Diagnostics  CBDL plays a central role in promoting the in vitro diagnostics (IVD) segment, responsible for essential laboratory technologies. Its main initiatives include:  ABIIS: Brazilian Alliance of Innovative Health Industry  ABIIS brings together associations and companies to promote innovation and sustainability in Brazil’s healthcare system. Its areas of action include:  SindHosp: Union of Hospitals, Clinics, and Laboratories of São Paulo  Although focused on healthcare institutions, SindHosp also indirectly impacts the medical devices market by representing the interests of hospitals and laboratories that use these technologies. The entity is dedicated to:  SBPC/ML: Brazilian Society of Clinical Pathology/Laboratory Medicine  SBPC/ML is a reference in the field of laboratory diagnostics and, although a scientific society, its actions directly impact the medical devices market. Its contributions include:  ANAHP: National Association of Private Hospitals  ANAHP represents private hospitals of excellence in Brazil and, while focused on healthcare institutions, its actions influence the medical devices market by:  CMB: Confederation of Charitable Hospitals, Philanthropic Entities, and Mercy Hospitals  CMB is one of the largest representative entities for philanthropic hospitals in Brazil, which are significant users of medical devices. The confederation focuses on:  ABRAIDI: Brazilian Association of Importers and Distributors of Healthcare Products  ABRAIDI plays a crucial role in representing companies that import and distribute medical devices in Brazil. Its initiatives include:  The Importance of Collaboration Among Entities  The medical devices market is vast and complex, requiring the collaboration of multiple entities to address challenges such as regulation, innovation, access, and sustainability. Representative institutions play complementary roles, working to:  Conclusion  Strengthening the medical devices market in Brazil depends on joint actions by different representative entities. Each organization, with its expertise and specific focus, contributes to efficient regulation, the promotion of innovation, and the guarantee of a competitive and sustainable environment. Understanding the role of these institutions is essential for professionals, companies, and managers seeking to develop impactful solutions in the healthcare sector.  References  For any questions, contact Brisa Advisors for specialized regulatory support.    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

The RDC 938/2024 resolution, published by Anvisa, introduces significant updates to the Good Storage Practices (GSP) for goods and products subject to health surveillance in bonded warehouses. Effective from March 3, 2025, this regulation replaces RDC 346/2002, aiming to enhance safety, quality, and efficiency in the country’s logistics operations.  Below, we explore the resolution’s key points, its impacts on the industry, and the necessary steps for compliance.  What Does RDC 938/2024 Establish?  RDC 938/2024 sets out clear and comprehensive guidelines for the storage of goods and products under health surveillance. It addresses aspects such as Quality Management System (QMS) implementation, infrastructure requirements, documentation, and training.  Scope:  Objectives:  Key Requirements of RDC 938/2024  The resolution introduces significant changes that will require operational adjustments from companies. Below are the highlights:  1. Quality Management System (QMS)  Companies must implement a robust QMS to monitor all stages of the storage process. This system should include:  2. Infrastructure and Facilities  Warehouses must meet the following specifications:  3. Temperature-Sensitive Products  Products sensitive to temperature require special attention. The resolution demands:  4. Qualification and Validation  All equipment and computerized systems impacting quality must be qualified or validated. This includes:  5. Documentation and Records  The resolution emphasizes strong document management practices:  Impacts on Companies  Compliance with RDC 938/2024 requires a comprehensive review of operations and investments in infrastructure, technology, and training. Key challenges and opportunities include:  Deadlines and Penalties  Anvisa has set specific deadlines for company compliance:  Non-compliance may result in:  How to Prepare?  To ensure compliance with RDC 938/2024, companies should:  Conclusion  RDC 938/2024 represents a significant advancement in the safety and efficiency of Brazil’s logistics sector. While the requirements are demanding, they also present opportunities for companies to enhance their operations and stand out in the market.  Adopting Good Storage Practices is not just about compliance—it’s about competitiveness and a commitment to quality.  📝 Access the translated version of RDC 938/22  RDC Nº 938/2024     The original language version of this announcement is the authorized official version. Translations are provided for convenience and should refer to the original language text, which is the only legally binding version.  Click the link to access the Original Version    For any questions, contact Brisa Advisors for specialized regulatory support.    Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

Brisa Advisors made its mark at MEDICA 2024, the world’s largest medical industry event, held from November 11 to 14 in Düsseldorf, Germany. This event showcased the latest advancements in medical devices and innovative technologies, offering an inspiring glimpse into the future of healthcare.  More than just exploring the vast exhibition space, we leveraged MEDICA 2024 as a strategic platform to strengthen connections and expand our horizons:  These interactions reaffirmed our commitment to excellence and innovation. Armed with the knowledge and connections gained, we are ready to transform these insights into even more impactful solutions for our clients and partners worldwide.  Click here to learn more about the event: https://brisa.com.br/brisa-advisors-at-medica-2024-connecting-innovations-to-the-brazilian-medical-device-market/  For any questions, contact Brisa Advisors for specialized regulatory support.    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

1. What is RDC 488/2021 and its Purpose?  RDC 488/2021 was established to regulate the importation of health products subject to sanitary surveillance by healthcare units, aiming to address specific needs in patient care, diagnosis, treatment, and rehabilitation.  Key aspects of the resolution include:  2. Who Can Import and Under What Conditions?  The importation governed by RDC 488/2021 can be performed by:  Important conditions:  Permitted Modalities:  3. Required Documents for the Importation Process  To proceed with importation, the following documents are essential:  Electronic document submissions require a digital signature with an ICP-Brasil certificate to ensure security and authenticity.  4. Exceptions: Non-Registered Products in ANVISA  RDC 488/2021 allows for the exceptional importation of non-registered products, provided the following conditions are met:  If the product has been previously authorized by ANVISA, the request analysis may be expedited based on prior decisions.  5. Impacts and Benefits of RDC 488/2021  This resolution offers significant benefits, such as:  However, strict adherence to the rules by all parties involved is crucial to avoid sanitary violations and ensure compliance.  Conclusion  RDC 488/2021 represents a major advancement for the healthcare sector, balancing speed and safety in product importation. For healthcare units and regulatory professionals, understanding and correctly applying the guidelines of this resolution is essential to providing quality medical care while adhering to legal requirements.  If you wish to learn more about implementing RDC 488/2021 in your professional context, consult experts or access the full text of the resolution here.  📝 Access RDC No. 488/2021  RDC Nº 488/2021    The text in the original language of this announcement is the only official and authorized version. Translations are provided solely for convenience and should refer to the original language text, which is the only version with legal effect.  For any questions, please contact Brisa Advisors for specialized regulatory support    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

The Brazilian Health Regulatory Agency (ANVISA) has published RDC No. 938/2024, establishing new provisions for Good Storage Practices (GSP) and regulating certification for bonded warehouses handling goods and products subject to health surveillance. The regulation will take effect on March 3, 2025, and has the potential to raise safety and quality standards in the logistics sector.  Key Points of RDC No. 938/2024  Scope and Applicability  Quality Management System (QMS)  Infrastructure and Storage  Staff Training  Documentation and Records  Good Storage Practices Certification  RDC No. 938/2024 introduces a voluntary certification for Good Storage Practices, valid for four years. This certification fosters:  Companies seeking certification must demonstrate full compliance with the technical requirements outlined in the regulation.  Deadlines and Adjustments  The regulation establishes critical deadlines for implementation:  Why Is This Resolution Important?  RDC No. 938/2024 aligns Brazil with international storage and health surveillance standards, promoting:  Conclusion  Compliance with RDC No. 938/2024 represents a milestone for Brazil’s logistics sector, requiring collective efforts from companies to implement structural and managerial changes. Pursuing voluntary certification, beyond merely meeting the requirements, can set organizations apart and ensure their relevance in the global market.  📝 Access RDC No. 938/2024  RDC Nº 938/2024    The text in the original language of this announcement is the only official and authorized version. Translations are provided solely for convenience and should refer to the original language text, which is the only version with legal effect.  📎 Click the link to access the Original Version  For any questions, please contact Brisa Advisors for specialized regulatory support    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

We are thrilled to announce that Brisa Advisors will be attending MEDICA 2024, the world’s largest event in the medical sector, taking place from November 11 to 14 in Düsseldorf, Germany. With over 40 years of history, this fair is a milestone on the calendar of specialists and is the largest global gathering of healthcare professionals, researchers, and business and political leaders. MEDICA brings together thousands of exhibitors from more than 50 countries and offers an extensive range of product categories, including imaging/diagnostic technology, laboratory equipment, diagnostic tests, physiotherapy/orthopedic technology, disposables, IT systems and solutions, and medical services. The event also includes a series of forums and conferences addressing medical technology topics, such as the MEDICA CONNECTED HEALTHCARE FORUM with the MEDICA START-UP COMPETITION, MEDICA HEALTH IT FORUM, MEDICA ECON FORUM, and MEDICA TECH FORUM. Highlights also include the German Hospital Conference, the MEDICA MEDICINE + SPORTS CONFERENCE, and the International Conference on Disaster and Military Medicine (DiMiMED). Why is MEDICA so vital? 🌍 Global Insight: The event brings together health experts and professionals from around the world, providing a global perspective on best practices and innovations in medicine. 🔬 Innovation: Advances in medical technology, groundbreaking devices, and cutting-edge healthcare solutions are showcased. This is where the most revolutionary ideas come to life. 🤝 Powerful Networking: MEDICA fosters an environment to establish valuable connections with peers, form strategic partnerships, and collaborate on projects that can change how healthcare is delivered. 📚 Continuous Learning: The outstanding educational program covers topics that shape modern medicine. Knowledge gained here can inspire significant innovations and advancements. As a market access and regulatory compliance specialist with ANVISA, Brisa Advisors provides essential support for companies interested in expanding into Brazil, ensuring a safe and competitive market entry process. If you wish to bring your products to Brazil with a reliable and efficient structure, schedule a meeting with us at MEDICA to explore the strategies Brisa Advisors can offer for your success in the Brazilian market. During MEDICA, our team will be available to discuss how we can assist your company—from selecting optimal sales channels to obtaining regulatory approvals and achieving effective commercialization. Book a meeting with us and discover how to accelerate the entry of your medical devices into Brazil. We look forward to seeing you at MEDICA 2024! Click to schedule your meeting For any questions, please contact Brisa Advisors for specialized regulatory support. Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br